atenolol has been researched along with Amyotrophic Lateral Sclerosis in 2 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salado, IG | 1 |
| Redondo, M | 1 |
| Bello, ML | 1 |
| Perez, C | 1 |
| Liachko, NF | 1 |
| Kraemer, BC | 1 |
| Miguel, L | 1 |
| Lecourtois, M | 1 |
| Gil, C | 2 |
| Martinez, A | 2 |
| Perez, DI | 1 |
| Nozal, V | 1 |
| Martínez-González, L | 1 |
| Gomez-Almeria, M | 1 |
| Gonzalo-Consuegra, C | 1 |
| Santana, P | 1 |
| Chaikuad, A | 1 |
| Pérez-Cuevas, E | 1 |
| Knapp, S | 1 |
| Lietha, D | 1 |
| Ramírez, D | 1 |
| Petralla, S | 1 |
| Monti, B | 1 |
| Martín-Requero, A | 1 |
| Palomo, V | 1 |
| de Lago, E | 1 |
2 other studies available for atenolol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain B | 2014 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; I | 2022 |